Navidea Biopharmaceuticals Inc (NAVBQ)

[sts66]

Appears the FDA caught NAVB off guard, very unusual for an FDA approval PR to come out before the company issues one, and it's also why the stock wasn't halted - approval came 6 wks early (PDUFA was April 30). Company came out with their own PR a few minutes ago:

http://finance.yahoo.com/news/fda-approves-navidea-lymphoseek-technetium-170700731.html

FDA Approves Navidea’s Lymphoseek® (technetium Tc 99m tilmanocept) Injection for Use in Lymphatic Mapping

The first receptor-targeted radiopharmaceutical approved for lymphatic mapping in breast cancer and melanoma patients

Company to Host Conference Call at 4:00 p.m., March 13, 2013
Business Wire

Press Release: Navidea Biopharmaceuticals, Inc. – 18 minutes ago